# Trastuzumab-Anns (Kanjinti)

Source: https://ourhealthnetwork.com/drugs/trastuzumab-anns
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Trastuzumab-Anns?

Trastuzumab-Anns (brand name: Kanjinti) is a her2/neu receptor antagonist. It is prescribed to treat gastrointestinal neoplasms, breast neoplasms.

## Brand names

Kanjinti

## Indications

Trastuzumab-Anns is prescribed for the treatment of gastrointestinal neoplasms and breast neoplasms.

## Conditions treated

- [Gastrointestinal Neoplasms](https://ourhealthnetwork.com/conditions/gastrointestinal-neoplasms)
- [Breast Neoplasms](https://ourhealthnetwork.com/conditions/breast-neoplasms)

## Mechanism of action

The HER2 (or c-erbB2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Trastuzumab products have been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2.

## Drug classification

- Established Pharmacologic Class: HER2/neu Receptor Antagonist [EPC]
- Mechanism of Action class: HER2/Neu/cerbB2 Antagonists [MoA]
- Route of administration: INTRAVENOUS

## Common side effects

chills, diarrhea, headache, nausea

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)